Evercore ISI Begins Coverage on Metsera (NASDAQ:MTSR)

Research analysts at Evercore ISI started coverage on shares of Metsera (NASDAQ:MTSR) in a report issued on Tuesday, MarketBeat.com reports. The firm set an “outperform” rating on the stock.

Metsera Price Performance

Shares of MTSR stock opened at $27.21 on Tuesday. Metsera has a 12-month low of $25.06 and a 12-month high of $32.81.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.